HUP0402401A2 - Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával - Google Patents

Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával

Info

Publication number
HUP0402401A2
HUP0402401A2 HU0402401A HUP0402401A HUP0402401A2 HU P0402401 A2 HUP0402401 A2 HU P0402401A2 HU 0402401 A HU0402401 A HU 0402401A HU P0402401 A HUP0402401 A HU P0402401A HU P0402401 A2 HUP0402401 A2 HU P0402401A2
Authority
HU
Hungary
Prior art keywords
treatment
cancer
farsenyl
combination
antineoplastic agents
Prior art date
Application number
HU0402401A
Other languages
English (en)
Inventor
David L. Cutler
Michael L. Meyers
Charles Baum
Sara L. Zaknoen
Original Assignee
Schering Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp. filed Critical Schering Corp.
Publication of HUP0402401A2 publication Critical patent/HUP0402401A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A találmány egy farnezil-protein transzferáz (FPT) inhibitoralkalmazására vonatkozik rák kezelésére szolgáló gyógyszerekelőállítására, ahol a kezelés magában foglalja az említett gyógyszerés egy vagy több, előnyösen legalább két különböző daganatellenes szerhatékony mennyiségének a beadását. A kezelendő rákok közé tartozik anemkissejtes tüdőrák, a CML, az AML, a nem Hodgkin-limfóma és amultiplex mielóma. Ó
HU0402401A 2001-11-30 2002-11-25 Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával HUP0402401A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33441101P 2001-11-30 2001-11-30
PCT/US2002/037954 WO2003047697A2 (en) 2001-11-30 2002-11-25 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer

Publications (1)

Publication Number Publication Date
HUP0402401A2 true HUP0402401A2 (hu) 2005-03-29

Family

ID=23307076

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402401A HUP0402401A2 (hu) 2001-11-30 2002-11-25 Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával

Country Status (13)

Country Link
US (2) US20030185831A1 (hu)
EP (1) EP1448268A2 (hu)
JP (1) JP2005511663A (hu)
CN (2) CN101181269A (hu)
AU (1) AU2002352941A1 (hu)
BR (1) BR0214564A (hu)
CA (1) CA2468839A1 (hu)
HU (1) HUP0402401A2 (hu)
MX (1) MXPA04005207A (hu)
NO (1) NO20042730L (hu)
NZ (1) NZ532562A (hu)
WO (1) WO2003047697A2 (hu)
ZA (1) ZA200403737B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0312821A (pt) * 2002-07-24 2005-04-19 Akira Ohtsuru 4-(4-metil-piperazin-1-il-metil)-n-[(4-metil-3-(4-piridin-3-i l)-pirimidin-2-il-amino)-fenil]-benzamida para tratar câncer anaplásico da tireóide
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
BRPI0416316A (pt) * 2003-11-06 2007-01-09 Schering Corp combinação de um inibidor da farnesil transferase com um agente anti-hormonal para o tratamento de cáncer de mama
AU2005216898A1 (en) * 2004-02-26 2005-09-09 The Penn State Research Foundation Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20080255171A1 (en) * 2005-10-07 2008-10-16 Manley Paul W Combination of Nilotinib with Farnesyl Transferase Inhibitors
MX2009004554A (es) * 2006-10-25 2009-05-11 Schering Corp Metodos discontinuos de tratamiento de cancer.
EP2088862A4 (en) * 2006-11-28 2009-12-02 Smithkline Beecham Cork Ltd METHOD OF TREATING CANCER

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
DK1041985T3 (da) * 1997-12-22 2006-06-19 Schering Corp Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
WO2001056552A2 (en) * 2000-02-04 2001-08-09 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating breast cancer
JP2003523381A (ja) * 2000-02-24 2003-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 投与レジメン
CA2397425A1 (en) * 2000-02-29 2001-09-07 Ivan David Horak Farnesyl protein transferase inhibitor combinations with taxane compounds
EP1261374A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
EP1322334A2 (en) * 2000-10-05 2003-07-02 George Q. Daley Methods of inducing cancer cell death and tumor regression

Also Published As

Publication number Publication date
NO20042730L (no) 2004-06-29
US20030185831A1 (en) 2003-10-02
WO2003047697A3 (en) 2003-10-30
NZ532562A (en) 2007-02-23
US20060183765A1 (en) 2006-08-17
MXPA04005207A (es) 2004-08-19
CN101181269A (zh) 2008-05-21
JP2005511663A (ja) 2005-04-28
CN1617755A (zh) 2005-05-18
CA2468839A1 (en) 2003-06-12
AU2002352941A1 (en) 2003-06-17
EP1448268A2 (en) 2004-08-25
ZA200403737B (en) 2005-05-23
BR0214564A (pt) 2004-11-09
WO2003047697A2 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
MXPA04005425A (es) Uso de inhibidores de farnesil proteina transferasa y por lo menos dos agentes antineoplasicos en el tratamiento de cancer.
YU77000A (sh) Primena peg-ifn-alfa i ribavirina za lečenje hroničnog hepatitisa c
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
SI1689724T1 (sl) Spojine kinazolinona kot sredstva proti raku
WO2001087306A8 (en) Compositions and methods for the treatment of colorectal cancer
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
HRPK20041072B3 (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
IL150953A0 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
HUP0402401A2 (hu) Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
YU84503A (sh) Upotreba azitromicina za pripremanje leka za lečenje neinfektivnih inflamatornih oboljenja
WO2005025501A3 (en) Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer
MY134690A (en) Antitumor therapy comprising distamycin derivatives.
HUP0203153A2 (hu) Kombinációs kemoterápia
NO970178D0 (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
HUP0101947A2 (hu) Tumorok kezelésére szolgáló kombinációs készítmény
WO2002078690A3 (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
EP1374873A4 (en) USE OF N-ACETYL-D-GLUCOSAMINE IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE SUPPRESSION OF SIDE EFFECTS CAUSED BY RADIATION THERAPY AND CHEMOTHERAPY
EP1390027A4 (en) COMPOSITION WITH DEMETHYLCANTHARIDINE IN COMBINATION WITH PLATINUM-CONTAINING ANTI-VITAL AGENTS AND THEIR USE
WO1999043332A8 (en) Antitumor combination comprising epirubicin and gemcitabine for the treatment of non-small-cell lung cancer
WO2003006689A3 (en) Diagnosis and treatment of diseases associated with altered expression of hipk1
UA83204C2 (ru) Комбинированная терапия для лечения острого лейкоза и миелодиспластичного синдрома

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees